Loading…

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

Expression of oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and transforming growth factor-α (TGFα) proteins was assessed by immunocytochemistry on primary breast cancer specimens obtained before and following short-term (7-day) presurgical exposure to pure anti-oestrogen (7α- [9-...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 1996-03, Vol.32 (3), p.413-416
Main Authors: McClelland, R.A., Gee, J.M.W., Francis, A.B., Robertson, J.F.R., Blarney, R.W., Wakeling, A.E., Nicholson, R.I.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Expression of oestrogen receptor (ER), epidermal growth factor receptor (EGFR) and transforming growth factor-α (TGFα) proteins was assessed by immunocytochemistry on primary breast cancer specimens obtained before and following short-term (7-day) presurgical exposure to pure anti-oestrogen (7α- [9- (4,4,5,5,5-pentafluoropentylsulphinyl) nonyl] estra-1,3,5, (10)-triene-3,17 β-diol, ICI 182780) treatment and compared with no-treatment controls. Paired needle-core and mastectomy samples were obtained from 21 patients. Effects of ICI 182780 (10 −7M) on MCF7 breast cancer cell ER, EGFR and TGFα expression were also examined over 14 days. ER protein was significantly suppressed by ICI 182780 in vivo (P = 0.009) and comparative analysis of short term ICI 182780 effects in vitro, using ER-positive MCF7 cells, gave largely equivalent results. EGFR and TGFα protein levels were unaltered by treatment. ICI 182780 suppresses ER without a concomitant rise in either EGFR or TGFα.
ISSN:0959-8049
1879-0852
DOI:10.1016/0959-8049(95)00517-X